Two of ten patients treated in a prospective study of topical imiquimod (IMQ), a synthetic imidazoquinoline and Toll-like receptor (TLR)-7 agonist, [13] applied to the involved skin overlying a large primary breast cancer had a complete and durable clinical response (CR) of all metastatic sites during subsequent therapy. Here, TLR7 is linked to breast carcinoma.